This is the revision of the year 25-29 competitive renewal of the UNC Breast Cancer SPORE, one of the original 1992 SPOREs, which has contributed key findings in breast cancer translational research in minority disparities, genomic analysis, molecular subtyping and therapeutic resistance, while advancing new technology and developing junior faculty into translational research leaders. The constant since 1992 is a population- based, biospecimen-rich, epidemiological and clinical infrastructure, the Carolina Breast Cancer Study (CBCS). CBCS Phase 3 has finished accrual of an additional 3,000 cases and embarked on a ten-year follow- up with treatment, adherence, and outcome data. CBCS oversamples African Americans (AA) and patients aged 50 or younger to provide one of the largest population-based studies of age and race disparities. CBCS has made seminal contributions to our understanding of triple negative breast cancer (TNBC) and other breast cancer subtypes in North Carolina?s AA population with over 150 papers published. For example, our SPORE has published articles characterizing Basal-like TNBC that have been cited over 23,000 times. With substantial institutional investment, the UNC SPORE: i) Incorporates new technology and novel methods; ii) Develops infrastructure that provides new directions; and iii) Promotes career advancement for junior and mid-level faculty from the population, basic and clinical sciences. In the last 5 years, the CEP and DRP produced seven Komen Catalyst Awardees. The CEP brought 13 new faculty to the SPORE, 5 of them women and 3 minorities. The DRP funded collaborative projects between: engineers and clinicians to produce unique instruments and methods for early detection; immunologists and geneticists to study breast cancer immune infiltrates and responses; and outcomes researchers, clinicians and programmers to create new databases to study breast cancer care delivery in North Carolina. With EAB and Executive Committee input, the multi-PIs Chuck Perou and Shelley Earp with clinician co-lead Lisa Carey selected 4 projects for this revised renewal, focusing on minority disparities, developing a new understanding of resistance to immuno- and chemotherapies, and developing novel, clinically practical, predictive biomarkers. Project #1 ? The Carolina Breast Cancer Study (Troester, PhD and Carey, MD, MSc) will explore biologic and genomic differences in AA (1500) and white (1500) tumor specimens relating those to multiple patient-level parameters. The other projects are: Project #2 Inflammatory Signaling and ER+ Breast Cancer Therapeutic Resistance (Franco, PhD, Baldwin, PhD and Dees, MD, MSc); #3 Development of Chemotherapy and Immunotherapy Biomarkers for TNBC (Perou, PhD and Carey, MD, MSc) and #4 Therapeutic Approaches to the Adaptive Chromatin Remodeling that Underlies Resistance (Johnson, PhD and Earp, MD).

Public Health Relevance

Overall Narrative The UNC Breast Cancer SPORE, funded since 1992, continually updates its approaches through recruitment and development of talented faculty and investment in genomic, early detection and therapeutic technology. The UNC SPORE has had an emphasis over more than two decades on minority disparities through the unique population-based Carolina Breast Cancer Study and other initiatives; the proposed projects will focus on understanding the correlates and causes of disparate survival outcomes between African-Americans and whites, the influence of inflammatory signaling in ER+ disease, developing clinically practical molecular and immunologic biomarkers of response to existing and new treatments, and how to reverse adaptive reprogramming that results in rapid resistance to targeted agents in triple negative breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA058223-24A1
Application #
9487494
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Courtney, Joyann
Project Start
1997-08-05
Project End
2023-08-31
Budget Start
2018-09-01
Budget End
2019-08-31
Support Year
24
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Williams, Michelle M; Lee, Linus; Werfel, Thomas et al. (2018) Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death Dis 9:21
Allott, Emma H; Geradts, Joseph; Cohen, Stephanie M et al. (2018) Frequency of breast cancer subtypes among African American women in the AMBER consortium. Breast Cancer Res 20:12
Matsunuma, Ryoichi; Chan, Doug W; Kim, Beom-Jun et al. (2018) DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer. Proc Natl Acad Sci U S A 115:E11978-E11987
Panda, Anshuman; de Cubas, Aguirre A; Stein, Mark et al. (2018) Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. JCI Insight 3:
Sharma, Priyanka; López-Tarruella, Sara; García-Saenz, José Angel et al. (2018) Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. Clin Cancer Res 24:5820-5829
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
Kumar, Sunil; Lindsay, Daniel; Chen, Q Brent et al. (2018) Tracking plasma DNA mutation dynamics in estrogen receptor positive metastatic breast cancer with dPCR-SEQ. NPJ Breast Cancer 4:39
Smith, Christof C; Beckermann, Kathryn E; Bortone, Dante S et al. (2018) Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. J Clin Invest 128:4804-4820
Wheeler, Stephanie B; Spencer, Jennifer C; Pinheiro, Laura C et al. (2018) Financial Impact of Breast Cancer in Black Versus White Women. J Clin Oncol 36:1695-1701
Hong, Chi-Chen; Sucheston-Campbell, Lara E; Liu, Song et al. (2018) Genetic Variants in Immune-Related Pathways and Breast Cancer Risk in African American Women in the AMBER Consortium. Cancer Epidemiol Biomarkers Prev 27:321-330

Showing the most recent 10 out of 598 publications